The shift in the fatty acid composition of the circulating lipidome in Alzheimer’s disease

by Clinical Neuropsychologist | Wednesday, March 27, 2024 | Dementia

Abstract INTRODUCTION Fatty acids (FAs) are the building blocks of complex lipids and signaling compounds; the role of the lipidome fatty acid profile (LFA) in AD progression remains unclear. METHODS The LFA of plasma and cerebrospinal fluid (CSF) samples from 289...

Gene networks and systems biology in Alzheimer’s disease: Insights from multi‐omics approaches

by Clinical Neuropsychologist | Wednesday, March 27, 2024 | Dementia

Abstract Despite numerous studies in the field of dementia and Alzheimer’s disease (AD), a comprehensive understanding of this devastating disease remains elusive. Bulk transcriptomics have provided insights into the underlying genetic factors at a high level....

Correction to “Feasibility of a remote dance intervention for institutionalized older people with cognitive impairment”

by Clinical Neuropsychologist | Wednesday, March 27, 2024 | Dementia

Alzheimer’s &Dementia, EarlyView. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: | March 27, 2024 Wiley: Alzheimer’s & Dementia: Table...

Ethical considerations for the use of anti‐amyloid immunotherapy in patients with early Alzheimer’s disease

by Clinical Neuropsychologist | Tuesday, March 26, 2024 | Dementia

Alzheimer’s &Dementia, EarlyView. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: Susanne J. van Veluw, Michael J. Young | March 26, 2024 Wiley:...

Plasma glial fibrillary acidic protein in the visual and language variants of Alzheimer’s disease

by Clinical Neuropsychologist | Tuesday, March 26, 2024 | Dementia

Abstract INTRODUCTION Glial fibrillary acidic protein (GFAP) in plasma is a proxy for astrocytic activity and is elevated in amyloid-β (Aβ)-positive individuals, making GFAP a potential blood-based biomarker for Alzheimer’s disease (AD). METHODS We assessed...

Novel ultrasensitive immunoassay for the selective quantification of tau oligomers and related soluble aggregates

by Clinical Neuropsychologist | Saturday, March 23, 2024 | Dementia

Abstract INTRODUCTION Tau aggregation into paired helical filaments and neurofibrillary tangles is characteristic of Alzheimer’s disease (AD) and related disorders. However, biochemical assays for the quantification of soluble, earlier-stage tau aggregates are...